How would you treat high risk prostate adenocarcinoma who relapsed after RT and ADT with a very low PSA, widespread mets to bone and soft tissue who is progressing on ADT, docetaxel and carboplatin?

Topics: Genitourinary Cancers • Prostate Cancer • Medical Oncology

No targetable mutations detected

Answer from: Medical Oncologist at Community Practice

Difficult situation, this patient likely has neuroendocrine differentiation. I would check for markers like NSE, chromogranin if positive, then can make the case of treating as small cell ca progressed on platinum based chemotherapy and treat with lurbinectedin (Trigo et al., PMID 32224306).PSMA bas...

Comments

Medical Oncologist at Northwestern Medical Group
I generally agree with the concern for neuro endoc...

Related Questions